Streetbeat News

AWKNF

Awakn Life Sciences Corp

Industry

Research and Development in Biotechnology

Open

0.08

Mkt cap

2.7M

Volume

8.2K

High

0.08

P/E Ratio

-1.08

52-wk high

0.19

Low

0.07

Div yield

N/A

52-wk low

0.05

Awakn Life Sciences Corp. has entered into a binding letter of intent for its acquisition by Graft Polymer (UK) PLC. The acquisition will involve all common shares, restricted share units, and deferred share units of Awakn, to be executed through a statutory plan of arrangement in British Columbia.

Portfolio Pulse from

December 16, 2024 | 1:45 pm

Awakn Life Sciences Corp. announced promising preclinical results for its aminoindane series, AW21003, aimed at treating trauma-related mental health disorders like PTSD.

Portfolio Pulse from

December 10, 2024 | 10:45 pm

Awakn Life Sciences Corp. (OTC:AWKNF) has partnered with the University of Nottingham for preclinical testing of its aminoindane compound, aimed at treating trauma-related mental health disorders like PTSD. The study will use rodent models to assess the compound's efficacy, with results expected by the end of 2024.

Portfolio Pulse from Juan Spínelli

October 15, 2024 | 5:04 pm

Awakn Life Sciences Corp. (OTCQB:AWKNF) has doubled its private placement financing to $2 million due to increased investor interest. The funds will support the company's R&D, focusing on treatments for Alcohol Use Disorder (AUD).

Portfolio Pulse from Juan Spínelli

September 18, 2024 | 3:55 pm

The article provides a comprehensive roundup of recent developments in the psychedelics field, including research findings, global regulatory perspectives, therapeutic applications, and business news. Key highlights include potential roles of psilocybin in dementia prevention and psychological flexibility, global legalization trends, and various companies' strategic moves such as voluntary delistings, partnership agreements, financial results, and patent filings related to psychedelic therapies.

Portfolio Pulse from Lara Goldstein

April 17, 2024 | 1:13 pm

President Biden signed the 2024 NDAA, which includes funding for clinical trials with psychedelics for active military members. Robert F. Kennedy Jr. expressed support for psychedelics in mental health treatment. Incannex Healthcare (NASDAQ:IXHL) is set to open Australia's first dedicated psychedelic-assisted therapy clinic. Psychedelics stocks showed varied performance, with COMPASS Pathways (NASDAQ:CMPS) closing at $8.75, and AdvisorShares Psychedelics ETF (NYSE:PSIL) closing at $1.42.

Portfolio Pulse from Lara Goldstein

December 27, 2023 | 3:09 pm

Professor David Nutt, a renowned researcher in cognitive sciences, addiction, cannabis and psychedelics, has been ranked the world's top psychopharmacologist by ScholarGPS, a company owned by Meta Analytics LLC. Nutt's contributions include over 1000 research papers, 27 books, and eight government reports on drugs. He is also the founder and chair of the national nonprofit Drug Science and serves as Chief Research Officer at Awakn Life Sciences (OTC:AWKNF).

Portfolio Pulse from Lara Goldstein

October 16, 2023 | 12:06 am

The Usona Institute has shared positive results from its Phase 2 trial assessing a single 25mg synthetic psilocybin dose for adults with Major Depressive Disorder. COMPASS Pathways (NASDAQ:CMPS) has also shared results from research on its novel AI technologies to support proprietary COMP360 psilocybin treatment for Treatment-Resistant Depression. In the UK, drug policy reform is underway, with a report urging the reclassification of psilocybin mushrooms and other psychedelics to Schedule 2. Several US states are also moving reform bills concerning the study or legalization of psychedelic substances for therapeutic purposes. The AdvisorShares Psychedelics ETF (NYSE:PSIL) opened at $1.79 on September 5, recovering from the prior week’s $1.65.

Portfolio Pulse from Lara Goldstein

September 11, 2023 | 1:34 pm

Awakn Life Sciences Corp. (OTC:AWKNF) has submitted a Clinical Trial Application (CTA) for a phase III clinical trial for its leading program, AWKN-P001, designed for the treatment of Severe Alcohol Use Disorder (SAUD). The trial will be conducted at ten UK National Health Service (NHS) sites and will involve 280 participants. The company expects to receive feedback on the CTA in the coming months and aims to commence treatment in late Q4 2023 or early Q1 2024.

Portfolio Pulse from The Dales Report

September 06, 2023 | 9:27 pm

The American Psychedelic Practitioners Association and BrainFutures have published the first-ever professional practice guidelines for psychedelic-assisted therapy. Algernon NeuroScience, a subsidiary of Algernon Pharmaceuticals, has finalized its clinical trial design for a phase 2 DMT stroke study. Atai Life Sciences, MindMed, and COMPASS Pathways have reported their Q2 2023 financial results. AdvisorShares Psychedelics ETF has seen a decrease in its weekly performance.

Portfolio Pulse from Lara Goldstein

August 14, 2023 | 1:47 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.